Toxicological and clinical computational analysis and the US FDA/CDER

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 1, 2007, Pages 109-124

  Benz, R Daniel ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Computational toxicology; Predictive modeling; QSAR; Quantitative structure activity relationship

Indexed keywords

METHYLTHIOURACIL; NEW DRUG; DRUG;

AUTOMATED PATTERN RECOGNITION; BIOLOGICAL ACTIVITY; CARCINOGENICITY; COMPUTER PROGRAM; DATA BASE; DECISION SUPPORT SYSTEM; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GENETIC ALGORITHM; GENOTOXICITY; HUMAN; LIVER TOXICITY; MATHEMATICAL COMPUTING; MAXIMUM TOLERATED DOSE; MUTAGENICITY; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPRODUCTIVE TOXICITY; REVIEW; SENSITIVITY AND SPECIFICITY; TERATOGENICITY; TOXICITY TESTING; TOXICOLOGICAL PARAMETERS; UNITED STATES; ANIMAL; CHEMISTRY; COMPUTER SIMULATION; METHODOLOGY; THEORETICAL MODEL; TOXICOLOGY;

ANIMALS; COMPUTER SIMULATION; DATABASES; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TOXICOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34250306426     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.1.109     Document Type: Review

References (17)

1. JOHNSON MA, MAGGIORA GM: Concepts and Applications of Molecular Similarity. Wiley, New York, USA (1990).
2. MATTHEWS EJ, CONTRERA JF: A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR ES software. Regul. Toxicol. Pharmacol. (1998) 28:242-264.
3. CONTRERA JF, MATTHEWS EJ, BENZ RD: Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regul. Toxicol. Pharmacol. (2003) 38:243-259.
4. MATTHEWS EJ, KRUHLAK NL, CIMINO MC, BENZ RD, CONTRERA JF: An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints. Regul. Toxicol. Pharmacol. (2006) 44:83-96.
5. CONTRERA JF, MATTHEWS EJ, KRUHLAK NL, BENZ RD: In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. Regul. Toxicol. Pharmacol. (2005) 43:313-323.
6. MATTHEWS EJ, BENZ RD, KRUHLAK NL, CONTRERA JF: Analysis of reproductive and developmental toxicity data: I. Development of weight of evidence QSAR database. Regul. Toxicol. Pharmacol. (2007) (In Press)
7. MATTHEWS EJ, KRUHLAK NL, BENZ RD, CONTRERA JF: Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. Curr. Drug Disc. Technol. (2004) 1:61-76.
8. CONTRERA JF, MATTHEWS EJ, KRUHLAK NL, BENZ PLD: Estimating the safe starting dose in Phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regul. Toxicol. Pharmacol. (2004) 40:185-206.
9. KLOPMAN G: Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules. J. Am. Chem. Soc. (1984) 106:7315-7320.
10. CONTRERA JF, MACLAUGHLIN P, HALL LH, KIER LB: QSAR modelling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr. Drug Discov. Tecnol. (2005) 2:55-67.
11. COOPER JA, SARACCI R, COLE P: Describing the validity of carcinogen screening tests. Br. J. Cancer (1979) 39:87-89.
12. MATTHEWS EJ, KRUHLAK NL, CIMINO MC, BENZ RD, CONTRERA JF: Analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. Regul Toxicol. Pharmacol. (2006) 44:97-110.
13. MATTHEWS EJ, KRUHLAK NL, BENZ RD, IVANOV J, KLOPMAN G, CONTRERA JF: A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of Q6SAR models to predict activities of untested chemicals. Regul. Toxicol. Pharmacol. (2007) (In Press).
14. BAILEY AB, CHANDERBHAN R, COLLAZO-BRAIER N, CHEESEMAN MA, TWAROSKI ML: The use of structure-activity relationship analysis in the food contact notification program. Regul. Toxicol. Pharmacol. (2005) 42:225-235.
15. KRUHLAK NL, BENZ RD, MATTHEWS EJ, CONTRERA JF: Progress in QSAR toxicity screening of impurities in pharmaceuticals and other FDA regulated products. Adv. Drug Deliv. Rev. (2007) (In Press).
16. GREENE N: Computer systems for the prediction of toxicity: an update. Adv. Drug Deliv. Rev. (2002) 54:417-431.
17. SNYDER DR, PEARL GS, MANDAKAS G, CHOY WN, GOODSAID F, ROSENBLUM IY: Assessment of the sensitivity of the computational programs DEREK, TOPKAT and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ. Mol. Mutagen. (2004) 43:143-158.